These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38864598)

  • 1. Efficacy of rifapentine and other rifamycins against
    Miller HK; Kersh GJ
    Microbiol Spectr; 2024 Jul; 12(7):e0103424. PubMed ID: 38864598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells.
    Fullerton MS; Colonne PM; Dragan AL; Brann KR; Kurten RC; Voth DE
    mSphere; 2021 Aug; 6(4):e0044221. PubMed ID: 34232075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
    Spyridaki I; Psaroulaki A; Vranakis I; Tselentis Y; Gikas A
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2690-2. PubMed ID: 19332671
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Albano M; Karau MJ; Greenwood-Quaintance KE; Osmon DR; Oravec CP; Berry DJ; Abdel MP; Patel R
    Microbiol Spectr; 2021 Sep; 9(1):e0007121. PubMed ID: 34259553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Coxiella burnetii antibiotic susceptibilities by real-time PCR assay.
    Brennan RE; Samuel JE
    J Clin Microbiol; 2003 May; 41(5):1869-74. PubMed ID: 12734219
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Albano M; Karau MJ; Greenwood-Quaintance KE; Osmon DR; Oravec CP; Berry DJ; Abdel MP; Patel R
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
    Dhillon J; Mitchison DA
    Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii.
    Rolain JM; Maurin M; Raoult D
    Antimicrob Agents Chemother; 2001 Jan; 45(1):301-2. PubMed ID: 11120982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.
    Rastogi N; Goh KS; Berchel M; Bryskier A
    J Antimicrob Chemother; 2000 Oct; 46(4):565-70. PubMed ID: 11020253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of pH on Antibiotic Efficacy against Coxiella burnetii in Axenic Media.
    Smith CB; Evavold C; Kersh GJ
    Sci Rep; 2019 Dec; 9(1):18132. PubMed ID: 31792307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of telithromycin against thirteen new isolates of C. burnetii including three resistant to doxycycline.
    Rolain JM; Lambert F; Raoult D
    Ann N Y Acad Sci; 2005 Dec; 1063():252-6. PubMed ID: 16481522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.
    Gikas A; Spyridaki I; Scoulica E; Psaroulaki A; Tselentis Y
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3276-8. PubMed ID: 11600400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
    Dickinson JM; Mitchison DA
    Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine susceptibility determination of Coxiella burnetii in human embryonic lung (HEL) fibroblast cells.
    Angelakis E; Khalil JB; Le Bideau M; Perreal C; La Scola B; Raoult D
    Int J Antimicrob Agents; 2017 Jul; 50(1):106-109. PubMed ID: 28478211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.
    Heifets LB; Lindholm-Levy PJ; Flory MA
    Am Rev Respir Dis; 1990 Mar; 141(3):626-30. PubMed ID: 2155555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility to tetracycline and fluoroquinolones of Japanese isolates of Coxiella burnetii.
    Andoh M; Naganawa T; Yamaguchi T; Fukushi H; Hirai K
    Microbiol Immunol; 2004; 48(9):661-4. PubMed ID: 15383702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea.
    Lee Y; Kim SS; Choi SM; Bae CJ; Oh TH; Kim SE; Kim UJ; Kang SJ; Jung SI; Park KH
    J Glob Antimicrob Resist; 2022 Mar; 28():43-48. PubMed ID: 34920175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.
    Rolain JM; Boulos A; Mallet MN; Raoult D
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2673-6. PubMed ID: 15980335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of axenic media to determine antibiotic efficacy against coxiella burnetii.
    Clay KA; Hartley MG; Russell P; Norville IH
    Int J Antimicrob Agents; 2018 May; 51(5):806-808. PubMed ID: 28802854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic susceptibilities of two Coxiella burnetii isolates implicated in distinct clinical syndromes.
    Yeaman MR; Roman MJ; Baca OG
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1052-7. PubMed ID: 2782856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.